title: rHuEPO enhances the production of plasminogen activator inhibitor-1 in cultured endothelial cells.
abstract: The direct effects of recombinant human erythropoietin(rHuEPO) on coagulation and fibrinolysis factors were evaluated in a cultured endothelial cell (EC) system. Confluent quiescent ECs were incubated with or without 5.0 U/ml rHuEPO for 1, 6, and 18 hours, and supernatant concentrations of plasminogen activator inhibitor-1 (PAI-1): antigen (Ag), tissue plasminogen activator and thrombomodulin, and supernatant activities of tissue factor pathway inhibitor and von Willebrand factor were measured. The results showed that only PAI-1 levels were increased by the presence of rHuEPO. In order to assess the effect of rHuEPO on PAI-1 production by EC more precisely, confluent ECs were incubated with various doses of rHuEPO (0, 1.0, 2.5, 5.0, 10.0 U/ml) for 1, 6, 12, and 18 hours, and PAI-1:Ag concentrations in the supernatants of media were measured. PAI-1:Ag in the supernatants were increased by the presence of rHuEPO at all incubation times (P < 0.01) and the increase in PAI-1:Ag was dependent on rHuEPO concentration. The increases in PAI-1:Ag by 5.0 U/ml rHuEPO were comparable to those by 0.1 U/ml tumor necrosis factor-alpha, 1.0 microgram/ml lipopolysaccharide, and 0.5 U/ml thrombin. The increase in PAI-1:Ag by rHuEPO was suppressed by pre-incubation with 10 micrograms/ml cycloheximide (P < 0.01) or 0.2 microgram/ml actinomycin D (P < 0.01). These results indicate that rHuEPO directly stimulates PAI-1 production in cultured EC via de novo protein and RNA syntheses.
authors.affiliation: Department of Internal Medicine, Fujigaoka Hospital, Showa University, Yokohama, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Nagai
authors.forename: T
authors.initials: T
authors.lastname: Akizawa
authors.forename: S
authors.initials: S
authors.lastname: Kohjiro
authors.forename: F
authors.initials: F
authors.lastname: Koiwa
authors.forename: K
authors.initials: K
authors.lastname: Nabeshima
authors.forename: K
authors.initials: K
authors.lastname: Niikura
authors.forename: K
authors.initials: K
authors.lastname: Kino
authors.forename: N
authors.initials: N
authors.lastname: Kanamori
authors.forename: E
authors.initials: E
authors.lastname: Kinugasa
authors.forename: T
authors.initials: T
authors.lastname: Ideura
mesh_terms: D002478:Cells, Cultured; D003513:Cycloheximide / Q000494:pharmacology; D003609:Dactinomycin / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000378:metabolism*; D004921:Erythropoietin / Q000494:pharmacology*; D006801:Humans; D017395:Plasminogen Activator Inhibitor 1 / Q000096:biosynthesis*; D011994:Recombinant Proteins
chemical_list: D017395:Plasminogen Activator Inhibitor 1; D011994:Recombinant Proteins; D004921:Erythropoietin; D003609:Dactinomycin; D003513:Cycloheximide